Erasca, Inc. (ERAS)
D
Pipeline Grade
Financial Position (from SEC Filings)
$47.7M
Cash & Equivalents
$27.4M
Quarterly Burn Rate
5 mo
Est. Cash Runway
$5,763M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (6)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06346067 | A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) | PHASE3 | Active Not Recruiting | 78 |
| NCT06983743 | A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors | PHASE1 | Recruiting | 600 |
| NCT05907304 | A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations | PHASE1 | Active Not Recruiting | 86 |
| NCT05222802 | A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1) | PHASE1 | Active Not Recruiting | 52 |
| NCT07021898 | A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors. | PHASE1 | Recruiting | 200 |
| NCT04670679 | A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors | PHASE1 | Active Not Recruiting | 90 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.